News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Capstone Therapeutics (CAPS) Announces A Lipimetix Development, LLC Presentation At The American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit Of AEM-28 On Established Atherosclerotic Lesions



11/19/2013 9:18:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEMPE, Ariz. and BOSTON, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Capstone Therapeutics' (OTCQB:CAPS) joint venture, LipimetiX Development, LLC, today announced the presentation of pre-clinical data demonstrating the sustained benefit effect of their apolipoprotein E mimetic peptide (AEM-28) on established atherosclerotic lesions in Apo E null mice at the American Heart Association Scientific Sessions meeting, November 16 – 20, 2013, in Dallas, TX.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES